Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Fidaxomicin (Dificlir®) is recommended as an option for restricted use within NHS Wales. Fidaxomicin (Dificlir®) should be restricted for use in the following subpopulations within its licensed indication for the treatment of adults with Clostridium difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD):
Fidaxomicin (Dificlir®) should be prescribed on the advice of a consultant microbiologist, consistent with UK Health Security Agency guidance. Fidaxomicin (Dificlir®) is not recommended for use within NHS Wales outside the specified subpopulations. |
|||
|
|||
Medicine details |
|||
| Medicine name | fidaxomicin (Dificlir®) | ||
| Formulation | 200 mg film-coated tablet | ||
| Reference number | 847 | ||
| Indication | Treatment of adults with Clostridium difficile infections (CDI), also known as C. difficile-associated diarrhoea (CDAD). Consideration should be given to official guidelines on the appropriate use of antibacterial agents |
||
| Company | Astellas Pharma Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 3712 | ||
| NMG meeting date | 09/10/2012 | ||
| AWMSG meeting date | 14/11/2012 | ||
| Ratification by Welsh Government | 11/12/2012 | ||
| Date of issue | 13/12/2012 | ||
| Date of last review | November 2022 | ||
| Further information This appraisal recommendation was reviewed in November 2022. No new evidence was identified that is likely to significantly affect the current recommendation. Therefore, this recommendation has been transferred to AWMSG’s static list of medicine recommendations |
|||
| Scrutiny Panel meeting date | useMuraDefault | ||
| LOWMAG meeting date | useMuraDefault | ||
| OWMAG meeting date | useMuraDefault | ||